- Home
- STXS vs MOLN Comparison
STXS vs MOLN Comparison
Compare STXS & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STXS
- MOLN
- Stock Information
- Founded
- STXS 1990
- MOLN 2004
- Country
- STXS United States
- MOLN Switzerland
- Employees
- STXS N/A
- MOLN N/A
- Industry
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- MOLN
- Sector
- STXS Health Care
- MOLN
- Exchange
- STXS Nasdaq
- MOLN Nasdaq
- Market Cap
- STXS N/A
- MOLN 192.4M
- IPO Year
- STXS 2004
- MOLN 2021
- Fundamental
- Price
- STXS $2.49
- MOLN $5.04
- Analyst Decision
- STXS Strong Buy
- MOLN
- Analyst Count
- STXS 2
- MOLN 0
- Target Price
- STXS $4.50
- MOLN N/A
- AVG Volume (30 Days)
- STXS 412.8K
- MOLN 5.7K
- Earning Date
- STXS 03-03-2025
- MOLN 03-13-2025
- Dividend Yield
- STXS N/A
- MOLN N/A
- EPS Growth
- STXS N/A
- MOLN N/A
- EPS
- STXS N/A
- MOLN N/A
- Revenue
- STXS $25,143,000.00
- MOLN $7,105,397.00
- Revenue This Year
- STXS $3.73
- MOLN N/A
- Revenue Next Year
- STXS $54.27
- MOLN $29.41
- P/E Ratio
- STXS N/A
- MOLN N/A
- Revenue Growth
- STXS N/A
- MOLN N/A
- 52 Week Low
- STXS $1.66
- MOLN $3.32
- 52 Week High
- STXS $3.29
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- STXS 61.67
- MOLN 41.97
- Support Level
- STXS $2.26
- MOLN $5.22
- Resistance Level
- STXS $2.52
- MOLN $5.35
- Average True Range (ATR)
- STXS 0.13
- MOLN 0.12
- MACD
- STXS 0.03
- MOLN -0.03
- Stochastic Oscillator
- STXS 89.80
- MOLN 0.00
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.